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Phages that infect Clostridium difﬁcile were ﬁrst isolated for typing purposes in the
1980s, but their use was short lived. However, the rise of C. difﬁcile epidemics over
the last decade has triggered a resurgence of interest in using phages to combat this
pathogen. Phage therapy is an attractive treatment option for C. difﬁcile infection, however,
developing suitable phages is challenging. In this review we summarize the difﬁculties
faced by researchers in this ﬁeld, and we discuss the solutions and strategies used for
the development of C. difﬁcile phages for use as novel therapeutics. Epidemiological
data has highlighted the diversity and distribution of C. difﬁcile, and shown that novel
strains continue to emerge in clinical settings. In parallel with epidemiological studies,
advances in molecular biology have bolstered our understanding of C. difﬁcile biology, and
our knowledge of phage–host interactions in other bacterial species. These three ﬁelds of
biology have therefore paved the way for future work on C. difﬁcile phages to progress and
develop. Beneﬁts of usingC. difﬁcile phages as therapeutic agents include the fact that they
have highly speciﬁc interactions with their bacterial hosts. Studies also show that they can
reduce bacterial numbers in both in vitro and in vivo systems. Genetic analysis has revealed
the genomic diversity among these phages and provided an insight into their taxonomy and
evolution. No strictly virulent C. difﬁcile phages have been reported and this contributes
to the difﬁculties with their therapeutic exploitation. Although treatment approaches using
the phage-encoded endolysin protein have been explored, the beneﬁts of using “whole-
phages” are such that they remain a major research focus. Whilst we don’t envisage
working with C. difﬁcile phages will be problem-free, sufﬁcient study should inform future
strategies to facilitate their development to combat this problematic pathogen.
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C. difﬁcile PATHOGENICITY, RIBOTYPES, AND
EPIDEMIOLOGY
Over the last few decades the enteric bacterium Clostridium difﬁ-
cile has emerged as an important nosocomial pathogen in clinical
settings globally, and in particular in Europe, the USA, Canada,
and Australia (Kuijper et al., 2006). Despite a general trend in
falling case numbers in these countries, C. difﬁcile infection (CDI)
remains a serious problem. For example there are an estimated
250,000 cases of CDI annually in the USA which result in approxi-
mately 14,000 deaths [Centers for Disease Control and Prevention
(CDC), 2013]. In addition to the human cost of the disease, the
ﬁnancial costs of treating and managing the infection are signif-
icant, with an estimated annual cost of $800 million in the USA
and €3000 million in Europe (Bouza, 2012). Number of CDI cases
in the UK decreased from 55,498 in 2007 to 14,687 in 2013 (Pub-
lic Health England, 2013), and this reduction is thought to be
attributed to the enormous effort that has been put into CDI (C.
difﬁcile infection) management strategies such as modiﬁed infec-
tion control procedures, antibiotic stewardship, and mandatory
reporting (Hughes et al., 2013). Therefore it is of concern that
despite these efforts, CDI remains a major healthcare challenge.
Abbreviations: CDI, Clostridium difﬁcile infection; CDS, coding DNA sequence;
CDT, Clostridium difﬁcile binary toxin encoded by two genes cdtA and cdtB;
CRISPR/Cas, a form of RNA based adaptive bacterial immunity to foreign DNA,
Clostridium difﬁcile infection is generally associated with the
production of up to three toxins; toxin A and toxin B, which are
encoded on a pathogenicity locus; the PaLoc, and the C. difﬁcile
binary toxin (CDT; Rupnik et al., 2009). These toxins disrupt the
epithelial cell layer of the colon and the resulting inﬂammatory
response contributes to the disease pathology. Symptoms range
from mild to serious diarrhea and, less commonly, to the develop-
ment of pseudomembranous colitis and toxic megacolon which
can be fatal (Libby and Bearman, 2009).
Several CDI epidemics have been linked to speciﬁc ribo-
types such as R027 and R078 (McDonald et al., 2005; Goorhuis
et al., 2008), but 100s of different ribotypes have been identi-
ﬁed (Wilcox et al., 2012). Ribotyping is a method of assigning
strain type based on the ampliﬁcation of the intergenic region
between the 16S and 23S rRNA gene, of which C. difﬁcile has
multiple copies (O’Neill et al., 1996). The use of next generation
sequencing (NGS) technology has revealed the genomic diver-
sity of important ribotypes, such as R027 (Stabler et al., 2009),
including phages and plasmids; HGT, horizontal gene transfer; MM,LTM, SMV and
SV, abbreviations used to describe the main four morphological types of C. difﬁcile
phage observed; NGS, next generation sequencing; PaLoc, pathogenecity locus of C.
difﬁcile containing genes involved in toxicity; tcdA, tcdB, tcdE, tcdC and tcdR; R027,
epidemic ribotype (strain) of C. difﬁcile; RCDI, recurrent C. difﬁcile infection; SNP,
single nucleotide polymorphism; TEM, transmission electron microscopy; TcdA
and TcdB, two toxins of C. difﬁcile encoded on the PaLoc.
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and one study has mapped the evolution and spread of this
ribotype in epidemics across the world highlighting their acqui-
sition of mobile genetic elements and antibiotic resistance genes
(He et al., 2012).
The ability of C. difﬁcile to form endospores permits its trans-
mission and persistence within clinical settings (Vonberg et al.,
2008). In contrast to nosocomial cases, a proportion of patients
with CDI acquire C. difﬁcile from sources outside the hospi-
tal environment (Eyre et al., 2012). The bacterium can colonize
individuals asymptomatically, and has reservoirs associated with
livestock, food and the natural environment (e.g., Hall and
O’Toole, 1935; al Saif and Brazier, 1996; Metcalf et al., 2010,
2011; Zidaric et al., 2010; Pasquale et al., 2011; Hargreaves et al.,
2013b). CDI has been suggested to be a zoonotic disease (Rup-
nik, 2007), and the cross-over of ribotypes between sources has
been observed (Janezic et al., 2012) as well as strain transmission
between livestock and humans (He et al., 2012). Establishing the
source of disease and ecology of this pathogenic species is impor-
tant for understandingC. difﬁcile’s emergence, predominance, and
pathology in clinical settings.
NOVEL WAYS TO COMBAT C. difﬁcile INFECTIONS
Current treatment of CDI is with one of three antibiotics: van-
comycin, metronidazole, or ﬁdaxomicin; however, treatment
failure and recurrent C. difﬁcile infection (RCDI) can occur after
treatment with any of these antibiotics (Surawicz et al., 2013). The
consequences of CDI and its continued clinical prevalence, com-
bined with limited treatment options, have motivated research
into alternative therapies to treat infections caused by this bac-
terium. These include new antibiotics, antimicrobial peptides,
bacteriocins, molecular inhibitors such as quorum sensing and
riboswitch ligands, toxin targeting molecules such as antibodies,
and the use of other bacteria as probiotics or fecal transplants.
These approaches are at various stages of development and are
discussed in a recent review and are not considered further here
[see review by (Zucca et al., 2013)].
Our review focuses on bacteriophage (phage) therapy to treat
C. difﬁcile. The use of phages as antimicrobials to treat a range
of bacterial diseases was developed shortly after their discovery in
1917, and their use as established therapeutics in some countries
is well documented (Kutter and Sulakvelidze, 2004). Many reviews
have been written on the efﬁcacy and safety of phage therapy (e.g.,
Abedon et al., 2011; Meaden and Koskella, 2013), and phages for
several infectious diseases have had notable successes and are at the
stage of clinical trial testing (Brüssow,2012). Herewe aim to review
the existing literature onC. difﬁcile phages and tohighlight thepros
and cons, challenges and solutions, associated with developing
them as a therapeutic.
C. difﬁcile PHAGE THERAPY
The use of C. difﬁcile phages as a treatment for CDI would involve
orally giving patients a C. difﬁcile speciﬁc phage preparation. The
phages would attach to the receptors on the C. difﬁcile cells, and
following the phageDNA entering the cell, would undergo replica-
tion and ultimately lyse the bacterial cell, releasing phage virions to
infect surrounding C. difﬁcile cells. This infection and lysis process
would be repeated until all the C. difﬁcile cells are killed and the
infection is cleared. The different stages of a lytic phage infection
of C. difﬁcile cells are illustrated in Figure 1.
There are several reasons why phage therapy would be par-
ticularly suited for treatment of CDI. One is that it offers select
advantages over existing antibiotic treatments. They include the
speciﬁc nature of the phage–bacterial interaction, which would
avoid exacerbating the gut dysbiosis (disruption of gut micro-
biota) that can be associated with treatment of CDI (Peterfreund
et al., 2012). Another advantage is the ability of phages to
replicate in a self-limiting manner at an infection focus. Impor-
tantly, the nature and the physical location of CDI may make
phage therapy a viable option, as there are likely to be rela-
tively few problems relating to the delivery of phages to the
colon. Often patients are infected by a single strain of C. dif-
ﬁcile (Eyre et al., 2012) and therefore there is not a complex
population of organisms to target. In summary, the clinical
need to develop new treatments to combat C. difﬁcile infec-
tion, combined with the problems of antibiotic associated gut
dysbiosis, and the physical location and general clonality of
the bacterium during infection makes a phage-based therapeutic
appealing.
It is perhaps not surprising then that the development of
therapeutic C. difﬁcile phages has attracted both academic and
commercial attention. However, in order for a phage-based ther-
apeutic to be successfully developed for this species, there are
several aspects of C. difﬁcile bacterial and phage biology that
need to be better understood. Considering the global impor-
tance of the pathogen, there has been little research on C. difﬁcile
phages compared to those which infect other pathogenic bac-
teria, and the information available on phages associated with
C. difﬁcile has been produced by relatively few research groups.
The lack of published work in this area can be seen from a
Pubmed search for terms “C. difﬁcile” and “phage” which at the
time of writing produced 45 results whereas “MRSA” and “phage”
resulted in 342 publications. The lack of research in this area
likely reﬂects the technical difﬁculties of working with anaer-
obes in general, and C. difﬁcile in particular. However, existing
research has provided key insights into the host–phage relation-
ship for this species and for the prospects of using phage therapy
against CDI.
SPECIFICITY-RELATED ADVANTAGES OF USING PHAGES FOR
TREATMENT OF C. difﬁcile
Clostridium difﬁcile infection is characterized by a dysbiosis of
the human gut microbiota (Manges et al., 2010). This imbalance
results in the overgrowth of endogenousC. difﬁcile (strains present
in the person) or exogenous C. difﬁcile (strains acquired from an
external source; Eyre et al., 2012). Although mixed infections with
multiple strains of C. difﬁcile occur, they are thought to do so at a
relatively low frequency, with the majority of infections caused by
a single strain (Eyre et al., 2012). Healthcare associated epidemics
have also been found to be dominated by single types (Loo, 2006;
Hubert et al., 2007; He et al., 2012). The limited C. difﬁcile strain
types in individual patients means that as long as the appropriate
phage is delivered, it is likely to be effective in clearing bacteria
from infected individuals, and from sets of individuals who are
infected during an outbreak setting.
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FIGURE 1 | Lysis of C. difﬁcile cells by myovirus phiCDHM1.
Transmission electron microscopy on microtomed samples showing
various stages of the phage lytic cycle. Clockwise from top left, a cell
with a single attached virion. Photomicrographs show an increasingly
granular appearance inside the cell, and the formation of putative capsid
structures at the outermost edges of the cell as indicated by arrows.
The ﬁnal image shows the contents of the lysed cell and multiple
phage particles. Scale bars represent 10 nm. TEM photomicrographs
courtesy of Katherine Hargreaves and Natalie Allcock, the Electron
Microscopy Facility, University of Leicester.
The co-evolution of host bacteria and their predatory phages
contributes toward the typically narrow host ranges reported for
many phages (Hyman and Abedon, 2010) and it is this precise tar-
geting of hosts that is exploited in the use of therapeutic phages
(Kropinski, 2006). The phage mechanism of action is in contrast
to the generally wide spectrum of activity that some antibiotics
exhibit. This includes vancomycin which is commonly used to
treat CDI and concomitantly exacerbates gut dysbiosis (Louie
et al., 2012). Phage therapy would take advantage of the highly
speciﬁc bacterial host ranges often exhibited by phages and there-
fore C. difﬁcile would be removed, but commensal bacteria would
be left intact.
Finally, another use of phage therapy would be not to replace
antibiotics, but to extend the usefulness of current antibiotics, as
the emergence of vancomycin and metronidazole resistance fol-
lowing treatment has been reported (Al-Nassir et al., 2008). Phages
could be used as a ﬁrst line of defense and antibiotics saved for a
last resort.
ADVANTAGES OF C. difﬁcile PHAGES TO TREAT BIOFILMS
Unlike antibiotics, phages are self-replicating. Once a suscepti-
ble host has been encountered and infected, phages replicate and
the delivery of treatment is ampliﬁed locally. This quality is par-
ticularly desirable when targeting bacterial bioﬁlms as they are
notoriously difﬁcult to penetrate and clear with antibiotics (Stew-
art and Costerton, 2001). Antibiotics have been shown in vitro to
be ineffectual in clearingC. difﬁcile bioﬁlms (Dapa andUnnikrish-
nan, 2013). This is of clinical signiﬁcance as C. difﬁcile aggregates
have been observed on the surface of caecum and colon tissues in
vivo (Buckley et al., 2011). The successful use of phages to pen-
etrate and disrupt bioﬁlms has been reported in several species,
for example in Pseudomonas aeruginosa (Hanlon et al., 2001; Fu
et al., 2010), Staphylococcus aureus (Kelly et al., 2012), and Campy-
lobacter jejuni (Siringan et al., 2011). The way in which phages
degrade bioﬁlms is often enzymatic with speciﬁc phages encod-
ing enzymes that are effective for a target species (Flemming and
Wingender, 2010). As C. difﬁcile can form bioﬁlms, it is possible
that C. difﬁcile phages will also have suitable speciﬁc enzymatic
ability.
MINIMIZING PROBLEMSWITH PHAGE RESISTANCE
The continuous evolutionary dynamics played out between bacte-
ria and phages has resulted in bacteria gainingmultiple and diverse
mechanisms to avoid and resist phage infection and predation
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(Labrie et al., 2010). However, phages have co-evolved alongside
their bacterial hosts and have counter-evolved strategies to main-
tain infectivity in what is often termed an“evolutionary arms race”
(Stern and Sorek, 2011). Although evolved resistance to phages has
not been reported in C. difﬁcile, genome sequencing has revealed
the presence of defense mechanisms including a CRISPR/Cas sys-
tem (Sebaihia et al., 2006), and active type I and type II restriction
modiﬁcation systems (Purdy et al., 2002).
Another way in which bacteria can evolve resistance is to ren-
der the phage receptors ineffective. Although no phage receptors
have been identiﬁed for C. difﬁcile phages, one study observed
that phages can adsorb onto diverse C. difﬁcile isolates, but were
unable to lyse them, suggesting that the receptor for the phage
used in this instance is well conserved even across isolates that
are not susceptible to lytic phage infection (Ramesh et al., 1999).
In some Gram-positive bacteria, such as S. aureus, the wall tei-
choic acid has been identiﬁed as being essential for phage infection
(Xia et al., 2011). Other candidate receptors for C. difﬁcile include
the S-layer that forms a paracrystaline layer around the whole
bacterial cell and is highly variable between strains (Calabi et al.,
2001). Although other sugars and proteins protrude through the
S-layer, they are present inmuch lower abundance (Fagan andFair-
weather, 2014). The S-layer has also been shown to be a receptor
in other species such as the Gram-negative bacterium Caulobacter
crescentus (Edwards and Smit, 1991).
Although the evolution of resistance to phages for therapeu-
tic purposes is of genuine concern, there are strategies that
can be used to minimize selection pressure for bacterial resis-
tance. One such approach is to infect the target organism with
a range of phages that have different receptors/modes of infec-
tion so changes in several targets would be required for phage
resistance to emerge. Importantly, evolving phage resistance
may not pose a signiﬁcant clinical challenge as it can come at
a cost to bacterial ﬁtness or virulence (Koskella et al., 2012).
This has been observed in vivo, in a phage therapy model of
C. jejuni infections in chickens where emergent phage resis-
tant mutants were not as competitive in growth assays as the
non-phage resistant parent strain (Scott et al., 2007). The rates
of phage resistance, or how they compare to antibiotic resis-
tance, have not been determined for C. difﬁcile, or indeed for
many pathogens. However, the impact of phage infection on
the development of antibiotic resistance has been investigated
in P. ﬂuorescens which showed that the application of phages
did not accelerate antibiotic resistance (Zhang and Buckling,
2012).
THE EARLY YEARS OF C. difﬁcile PHAGE RESEARCH; PHAGE
TYPING
Having discussed the potential beneﬁts of using C. difﬁcile phages
as a therapeutic, we now discuss research on C. difﬁcile phages
which has been conducted over the last three decades. They ﬁrst
became the subject of research attention following the realization
of the pathogenic nature of the bacterium in the 1970s. Figure 2
illustrates the progression of C. difﬁcile phage research, showing a
timeline of signiﬁcant milestones that followed on from the dis-
covery that C. difﬁcile caused pseudomembranous colitis (George
et al., 1978).
The lytic activity exhibited by C. difﬁcile phages was initially
exploited for typing purposes (Sell et al., 1983) and to provide
information on the transmission and epidemiology of C. difﬁ-
cile strains (Hawkins et al., 1984; Bacon et al., 1988). The carriage
of inducible prophages was also investigated in relation to bac-
terial phenotype and virulence, but did not establish a deﬁned
“lysotype” that reﬂected these phenotypic traits (Nagy and Foldes,
1991). Phage typing was ultimately not successful and its practice
was discontinued, this was in part due to their narrow host ranges
and strain typing was replaced by emerging molecular typing
techniques (Dei, 1989).
THE EARLY YEARS OF C. difﬁcile PHAGE RESEARCH; PHAGE
THERAPY
The ﬁrst in vivo model was developed using phage CD140 to
treat clindamycin induced CDI in hamsters (Ramesh et al., 1999).
This study demonstrated the potential usefulness of phages for
CDI, with 14/18 hamsters surviving infection with phage treat-
ment whereas none in the infected control group survived. In
the model, a single phage dose of 108 PFU was administered
immediately following challenging the hamsters with 103 CFU
of C. difﬁcile, in all phage treated animals. Two groups then
had phage doses administered at 8 hourly intervals up to 48 and
72 h. The longevity of phage therapy protection was tested by
re-challenging the surviving hamsters 2 weeks later with a sec-
ond administration of 103 CFU of C. difﬁcile, but no further
phage treatment. C. difﬁcile and phage counts were obtained
from the cecal contents of deceased animals and C. difﬁcile num-
bers in phage treated hamsters ranged from 1 × 103 CFU/g to
3 × 106 CFU/g. Phage were recovered from three of the infected
hamsters; two having 102 PFU/g and one with 104 PFU/g recov-
ered. Promisingly, the model showed that phage treatment could
protect hamsters against C. difﬁcile, that phages could survive in
the hamster gut and that C. difﬁcile isolates remained susceptible
to phage lysis when tested in vitro. However, the phage applica-
tion did not fully clear C. difﬁcile and protection was not long
lived. This is signiﬁcant when considering the scope for con-
tinued release of C. difﬁcile spores from treated patients into
the environment and the potential for RCDI episodes, which
is highly problematic in antibiotic treated patients (Johnson,
2009).
A CATALOG OF C. difﬁcile PHAGES
The ﬁrst reported isolation of C. difﬁcile phages was in 1983,
for the phages described above that were used for typing pur-
poses (Sell et al., 1983). Since then several phages have been
described in the literature (Hawkins et al., 1984; Mahony et al.,
1985, 1991; Bacon et al., 1988; Ramesh et al., 1999; Goh et al.,
2005a,b; Sekulovic et al., 2014). The levels of characterization vary
between the studies and include one or several of the following
types of data; host range studies, growth dynamics, morpho-
logical information, whole genome sequences, and comparative
genetics.
The phages from the studies listed above are mainly tem-
perate that were replicated on permissive hosts following either
their induction or spontaneous release from a bacterial lysogen.
In contrast, some phages were found as “free agents” in sample
Frontiers in Microbiology | Virology April 2014 | Volume 5 | Article 184 | 4
Hargreaves and Clokie C. difﬁcile phages
FIGURE 2 |Timeline charting major events of C. difﬁcile phage
research. Milestones are discussed in detail in the text and the
references are as follows; (1) George et al., 1978, (2) Sell et al., 1983, (3)
Mahony et al., 1985, (4) Nagy and Foldes, 1991, (5) Ramesh et al., 1999,
(6) Tan et al., 2001, (7) Goh et al., 2005a, (8) Sebaihia et al., 2006, (9)
Govind et al., 2006, (10) Goh et al., 2007, (11) Fortier and Moineau, 2007,
(12) Mayer et al., 2008, (13) Lavigne et al., 2009, (14) Govind et al., 2009,
(15) Horgan et al., 2010, (16) Meader et al., 2010, (17) Sekulovic et al.,
2011, (18) Govind et al., 2011, (19) Mayer et al., 2011, (20) Nale et al., 2012,
(21) Shan et al., 2012, (22) Meessen-Pinard et al., 2012, (23) Meader et al.,
2013, (24) Goh et al., 2013, (25) Hargreaves et al., 2013c, (26) Sekulovic
et al., 2014.
supernatants. Regardless of their origin, in all cases where the
phage genomes have been sequenced, putative integrase genes have
been identiﬁed which suggests that they can access the lysogenic
lifestyle. Indeed, investigations have shown that both environ-
mental and clinical derived C. difﬁcile strains carry a diverse and
prevalent set of prophages (Nagy and Foldes, 1991; Fortier and
Moineau, 2007; Nale et al., 2012; Shan et al., 2012; Hargreaves
et al., 2013b; Sekulovic et al., 2014). Collectively, these studies have
shown that although some speciﬁc prophages appear to be associ-
ated with speciﬁc ribotypes, for other groups there are high levels
of prophage diversity.
DEVELOPMENT OF ARTIFICIAL PHAGE TREATMENT MODELS
Two recent studies have used a one-phage/strain model in to
explore C. difﬁcile phage-host interactions in ex situ model sys-
tems. The ﬁrst involved studying their dynamics in a batch gut
model (Meader et al., 2010) and the second in amulti-vesselmodel
of the colon (Meader et al., 2013). The gut model was performed
in batch fermentations in which remedial and prophylactic treat-
ments were tested usingφCD27 (Meader et al., 2010). Results from
both approaches showed signiﬁcant decreases of CFU, as well as
reductions in the levels of toxins A and B relative to no phage
treatment. In contrast to the previous hamster model, lower mul-
tiplicity of infections (MOIs) were used; 7 in one replicate and
10 in the remaining two replicates. These MOIs resulted in dif-
ferent CFU counts between replicates, and C. difﬁcile was cleared
from the prophylaxis experiments when an MO1 of 10 was used.
PFU counts of φCD27 indicated that the phage did not replicate
in the model without C. difﬁcile present, and there was no reduc-
tion in gut bacterial numbers observed based on CFU counts.
The effect of metronidazole was tested in the model and found to
reduce commensal CFU counts, highlighting the potential to avoid
exacerbating the gut dysbiosis by phage treatment over antibiotic
therapy.
The second study used a colon model with three vessels to
represent the proximal and distal colons (Meader et al., 2013).
The phage φCD27 was applied daily over 35 days at an MOI
of 10. At days 14–21 clindamycin was added to the vessels to
produce conditions which would permit C. difﬁcile overgrowth.
Three replicates were performed, but results were ambiguous.
In two of the three, no vegetative C. difﬁcile were isolated, but
spore counts increased signiﬁcantly. The third replicate produced
CFU and spore counts similar to those of the controls. How-
ever, in all three replicates, the toxin levels decreased which is
similar to the results in the previous gut model. To determine
the cause of the different outcomes between replicates, C. dif-
ﬁcile recovered from the third were assessed for lysogeny. Nine
of ten colonies were positive for φCD27 following Mitomycin
C treatment and the authors suggest that a lysogen generated
early during the experiment went on to predominate the ves-
sel’s C. difﬁcile population. What caused this to occur in one
replicate and not the others is not known, but could have been
due to the composition of the donor gut microbiota. Lastly,
the effect on the gut bacterial population was also assessed in
this study, expanding on the previous work by using denatur-
ing gradient gel electrophoresis (DGGE) to proﬁle the bacterial
community. This was in addition to culture based detection and
conﬁrmed through these methods that phage infection did not
appear to alter the community structure. Thus, the colon model
data illustrates both the potential of phage therapy for CDI to clear
C. difﬁcile, as well as identifying other factors that could impact
phage treatment.
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ISOLATION OF C. difﬁcile PHAGES
Phages that infect C. difﬁcile have been notoriously difﬁcult
to isolate and propagate. Despite the early establishment that
multiple phage panels could lyse divergent C. difﬁcile strains,
studies have reported low frequencies of propagatable C. difﬁ-
cile temperate phages on alternative ‘host’ strains via the lytic
cycle; 0% (Nale et al., 2012), 3.9% (Sell et al., 1983), 2.1%
(Mahony et al., 1985), 3.3% (Mayer et al., 2008), 4.7% (Hor-
gan et al., 2010). This is despite the large numbers of strains
(25–94) being screened and used both as sources and as hosts
for phages. However, two studies have reported higher rates
of propagating phages, with 7.14% (Goh et al., 2005b), and
15.5% (Sekulovic et al., 2014). It is likely that strain related-
ness could inﬂuence the cross-infection of C. difﬁcile phages
which may explain low rates of some studies, for example
Nale et al. (2012) screened strains only belonging to R027. It is
also another motivating factor to seek phages from non-clinical
backgrounds.
Two independent research groups have reported unsuccess-
ful attempts to isolate free phages from patient, animal and
environmental samples despite the use of multiple hosts and
approaches (Goh et al., 2005b; Nale et al., 2012; Shan et al.,
2012). A third group used enrichment on 15 C. difﬁcile iso-
lates representing eight different ribotype groups, and although
they did not ﬁnd phage in sewage samples (30 samples),
they isolated four distinct phages from pooled stool sam-
ples (Meessen-Pinard et al., 2012). The researchers went on
to show that these were temperate phages which they also
detected as prophages in C. difﬁcile isolates from the same stool
samples.
The difﬁculties in isolating phages that can propagate on/infect
C. difﬁcile, have been attributed to its ability to undergo sporula-
tion, a process that may select for lysogenic infections over lytic
infections (Goh et al., 2005b). However, virulent phages have been
isolated for other spore forming bacteria [e.g., Bacillus cereus (El-
Arabi et al., 2013)] as well as for other Clostridium species [e.g.,
Clostridium perfringens (Volozhantsev et al., 2012)]. In all studies,
large scale screenings containing diverse strains appear to be nec-
essary to detect lytically active phages, and in addition to strain
relatedness, this may be explained by the high proportion and
diversity of prophage carriage between isolates (e.g., Hargreaves
et al., 2013b). C. difﬁcile lysogens are presumably able to resist
both superinfection and secondary infection by related phages
(e.g., Goh et al., 2005b). This has implications for the prospects of
phage therapy as these lysogens would require therapeutic prepa-
rations to encompass a wide enough diversity of phages to counter
their presence.
Although virulent phages are considered the most suitable for
phage therapy, Fortier and Sekulovic (2013) stated in their recent
review that they are not necessarily problem-free as phage therapy
candidates for this species, as strains canhave numerous prophages
and recombination could potentially occur with a virulent phage.
Thus, it is both pragmatic and pertinent to work with the phages
that exist and which demonstrate lytic activity on speciﬁc C. dif-
ﬁcile strains, but it is clearly advantageous to develop phages for
therapy that have minimal or preferably no temperate activity on
their target strains.
INSIGHTS FROM LYSOGENY IN C. difﬁcile; IMPACT ON HOST
PHYSIOLOGY
Another aspect of phage research in C. difﬁcile has been to deter-
mine their role in CDI and evolution of this pathogen (e.g., Nale
et al., 2012; Hargreaves et al., 2013b). It has been found that several
C. difﬁcile phages can modulate toxin production during lysogeny
(Goh et al., 2005a; Govind et al., 2009; Sekulovic et al., 2011). Fur-
ther genomic sequencing of isolated phages has described novel
phage types (Horgan et al., 2010; Meessen-Pinard et al., 2012) and
has revealed surprising genetic features, such as a phage with
homologs of the bacterial accessory gene regulatory (Agr) system
(Hargreaves et al., 2013c).
Collectively, the research described in this section has sig-
niﬁcantly expanded our understanding of the potential impact
of phage on C. difﬁcile physiology and on the suitability for
speciﬁc phages as therapeutic agents. Clearly when designing
phages as a therapeutic product, it is necessary to consider the
potential of lysogenic conversion, which is particularly important
in C. difﬁcile as lysogeny is common. Multiple phage inser-
tion sites have been identiﬁed (e.g., Govind et al., 2006; Goh
et al., 2007; Williams et al., 2013), and one phage, ϕCD38-2,
does not insert into the bacterial chromosome, but replicates
as a circular plasmid (Sekulovic et al., 2011). The instability of
both natural and laboratory generated lysogens is well docu-
mented, with C. difﬁcile cells found to spontaneously release
phages (e.g., Mahony et al., 1985), to differentially release their
multiple prophages depending on the antibiotic they are exposed
to (Sekulovic et al., 2014) as well as following freezing for stor-
age (Goh et al., 2005b). Further to this, Meessen-Pinard et al.
(2012) found that artiﬁcially generated lysogens produced sig-
niﬁcantly more phages when exposed to quinolones than the
wild-type lysogens did. The impact of sub-inhibitory concen-
trations of antibiotics on lysogen induction is of relevance as
antibiotic treatment may alter the levels of horizontal gene trans-
fer (HGT) in C. difﬁcile populations after exposure to quinolones
when in patients.
Therefore it is also important to determine how a phage that
has a tendency to lysogenize might behave during application
as a therapeutic and how it may inﬂuence the host bacterium.
These effects were examined in the phage, CD119, where lyso-
gens were shown to reduce toxin production (Govind et al., 2009).
This occurs via the action of the phage-encoded RepR, which
can bind to the promoter regions of tcdR, the positive regula-
tor of tcdA and tcdB. To assess the impact of lysogeny in vivo
during CDI, the same phage was applied in the Ramesh et al.
(1999) hamster model Govind et al. (2011). The results showed
that the phage could lysogenize under the conditions present in
the mammalian gut, as C. difﬁcile isolates were recovered that were
unsusceptible to infection with CD119. Prophage integration
was conﬁrmed using southern blots and PCR assays. Although
lysogeny is not desirable in a therapeutic model, all three of the
hamsters treated with phage outlived the controls. The lysogens
may have become attenuated as inferred by the decrease in toxin
production by the lysogens during culture. However, the toxin
levels in vivo were not presented and the authors state that they
will further determine the attenuation of strains in their future
work.
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Additionally, studies have shown that the physiological effect
of lysogeny varies according to phage or strains used (Goh et al.,
2005a; Sekulovic et al., 2011). Goh et al. (2005a) used three phages
to lysogenise different strains, and the resulting lysogens produced
increased levels of toxin B (3/5 lysogens) and toxin A (1/5 lyso-
gens). Different strains lysogenized with the same phage however,
differed in their toxin levels suggesting there is a strain-phage spe-
ciﬁc interplay that determines toxin levels. Sekulovic et al. (2011)
found that two out of ﬁve generatedϕCD38-2 lysogens also stimu-
lated toxin production. Interestingly, there was variation between
isolates of the same ribotype. Together, these studies demonstrate
that there is considerable variation in the physiological response of
phage infection. Further work to establish the underlying mecha-
nisms inﬂuencing toxin production in lysogens is needed to fully
assess the potential impact it could have on phage therapy in this
system.
INSIGHTS FROM LYSOGENY IN C. difﬁcile; HORIZONTAL
GENE TRANSFER
In addition to the introduction of novel genetic material in the
form of the prophage genome, phage infection also presents the
opportunity for generalized transduction to occur. The ability of
C. difﬁcile phages to mediate horizontal transfer of genetic mate-
rial in this manner is possible, but has been little studied. While
phage induced from a toxigenic strain did not convert a non-
toxigenic strain following lysogenisation (Goh et al., 2005b), a
recent study demonstrated that another phage, ϕC2, could medi-
ate the exchange of novel genetic material between C. difﬁcile
strains (Goh et al., 2013). ϕC2 was shown to transduce an antibi-
otic marker ermB carried on a transposon 13 kbp in size, after
infection with 107–108 PFUml−1 at MOIs of >0.02 (Goh et al.,
2013). The size of the transposon is slightly smaller than the
PaLoc which is ∼19.7 kbp (Cohen et al., 2000), and the length
of DNA that can be transferred remains to be determined. It is
known that C. difﬁcile phages can access a greater number of
strains than revealed by spot test assays alone, as demonstrated
by the absorption of phage CD140 to multiple strains without
producing lysis (Ramesh et al., 1999). Speciﬁc transducing phages
could serve as useful molecular tools, as genetic manipulation of
C. difﬁcile has been difﬁcult to achieve and there are relatively
few methods, although a lethal vector system (O’Connor et al.,
2006) and the ClosTron system (Heap et al., 2007) are available.
Alternatively, phages able to access a broad range of strains with-
out necessarily causing lysis could also be exploited for diagnostic
purposes, as similar phage-based detection methods have been
developed for other bacterial species such as ﬂuorescently labeled
phage, reporter phage or phage ampliﬁcation assays [see review
by (Rees and Dodd, 2006)]. More studies which further character-
ize phage host ranges are needed in order to assess the impact of
transduction between C. difﬁcile strains and how this may affect
their application.
C. difﬁcile PHAGE HOST RANGES
In general, data on host ranges shows that although some phages
can lyse a range of C. difﬁcile strains, typically host ranges are
restricted to one or a few strains. In the few studies where
ribotype information is presented, phages were found to infect
across ribotype groups, for example, the phage CD6356 can
infect 13/37 strains which belong to ﬁve ribotypes (Horgan et al.,
2010). The largest host range survey published showed that
ϕCD38-2 could infect 99/207 isolates tested (Sekulovic et al.,
2011). Although this seems high, 79 isolates belonged to the same
ribotype group and in total only 11 ribotypes were assayed.
The use of phage panels in early typing studies showed that the
inclusion of multiple phages resulted in the infection of many of
the tested strains by at least one phage (Sell et al., 1983). As these
studies predate ribotyping, no information is available about the
diversity of the panel of strains being tested (Hawkins et al., 1984;
Bacon et al., 1988). A recent study showed that distinct phages
induced from different ribotypes, including ϕCD38-2 could lyse
isolates belonging to several ribotypes of human and animal
origins (Sekulovic et al., 2014).
The ability of phages to infect a broad range of C. difﬁcile strains
is considered to be ideal for therapeutic purposes, and this could be
achieved by combining phages into a mixture or ‘cocktail.’ To date,
only single phages and single C. difﬁcile strains have been tested
in models for treatment (Ramesh et al., 1999; Meader et al., 2010,
2013; Govind et al., 2011). Extensive host range analysis relating
to genetic diversity of both strain and phages is currently being
investigated in this laboratory (unpublished). The goal of thiswork
is to determine the interactions between related phages and strains
and to develop optimal phage mixtures to treat clinically relevant
strains. Identifying phage receptors would help to inform these
studies and introduce the possibility of altering phages to target
a wider spectrum of strains. The mechanisms of phage resistance
in this species also need to be addressed in order to establish the
processes constraining the current narrow host ranges that have
been reported.
EFFECT OF C. difﬁcile PHAGES ON THE GUT MICROBIOTA
As previously highlighted, a key advantage that phages offer
for CDI treatment is their speciﬁcity, both to reduce dysbio-
sis of the gut microbiota associated with CDI and to mini-
mize the potential introduction of virulence genes from the
pathogenic C. difﬁcile to commensal organisms via transduc-
tion or lysogeny. In the gut and colon models, there was no
detected impact on gut commensal communities resulting from
phage treatment (Meader et al., 2010, 2013). Similarly, lysis of
closely and less-closely related bacterial species has been exam-
ined in several studies (Sell et al., 1983; Ramesh et al., 1999;
Goh et al., 2005b; Horgan et al., 2010). These species include an
assortment of clostridial species including C. sordellii, C. sep-
ticum, C. bifermentans, C. sphenoides, and C. perfringens with
no infective activity reported. However, some cross-infection
has been observed as temperate phages from C. sordellii were
found to be active on C. difﬁcile (Schallehn, 1985). In addi-
tion, the genetic similarity reported between sequenced phages
and other clostridial phages, such as PBSX (Govind et al., 2006),
suggests that these phages could share an ancestry or infect
across species. The impact C. difﬁcile phages have upon patient’s
gut microbiota would beneﬁt from the application of NGS
technology to investigate the bacterial-phage and phage–phage
dynamics during phage treatment. Bacterial and viral genomic
and transcriptomic data would be useful for determining the
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in situ population diversity and turnover of phages in order
to elucidate the dynamics in this system. Functional data from
transcriptomes and proteomes generated from infection models
would also provide valuable insight into C. difﬁcile phage–host
interactions.
GENOMIC FEATURES OF THE C. difﬁcile PHAGES
In this section of the review we discuss the insights into the
interactions between C. difﬁcile phages and their bacterial hosts
gained from the study of their genomes. Many phage genomes are
known to contain genes that can alter the physiology of the bac-
terial cell, including known toxin genes such as those carried by
Escherichia coli STX phages and the toxin converting C. botulinum
phage C1 [see review by (Boyd, 2012)]. In order to determine the
suitability of speciﬁc phages for therapeutic use it is necessary to
determine whether they carry genes that could enhance bacterial
virulence. Genome analysis can also reveal the genetic related-
ness between phages; this information can be used to inform
the development of phage cocktails or be useful for other phage
applications.
AllC. difﬁcile phage genomes sequenced to date are dsDNA and
belong to the Caudovirales (the order of tailed phages). They can
be grouped by particle morphology as they differ in size and mor-
phological type which includes the long tailed myoviruses (LTMs)
φCD27 and MMP04, the medium myoviruses (MMs) CD119,
ϕC2 and phiCDHM1, the small myovirus (SMV) MMP02
and two morphologically distinct siphoviruses (SVs) CD6356
and ϕCD38-2. In this section we have performed a comparative
genome analysis to highlight speciﬁc genome features of interest
(Figure 3). The genome ﬁgure has been produced using EasyFig
v.2.02 software (Sullivan et al., 2011) and subsequent analysis in
Clustal Omega (Sievers et al., 2011).
While no close homologs of the C. difﬁcile toxin genes are
present in any of the phage genomes, Goh et al. (2007) identiﬁed a
codingDNA sequence (CDS) inϕC2 that has a low level of similar-
ity to tcdB at the amino acid (aa) level. This CDS is located within a
proposed lysogenic conversion module of the genome, ﬂanked by
the lysis and lysogeny control genes and contains CDSs primarily
on the antisense strand. This region appears to be present in the
other medium and LTMs, but the gene content and exact location
of this region varies between phages.
Comparison of this region suggests that recombination
between phages may have occurred within this module, as the
genes appear to be in cassettes; for example the tcdB-like gene of
ϕC2 is adjacent to a putative enzyme (as it contains a DUF955
protein domain, PFam E-value 1.2e-19, with a characteristic H-E-
X-X-Hmotif at aa residues 80–84) and aCDSwhich encodes a pre-
dicted DNA directed RNA polymerase 7 kDa peptide/zinc ﬁnger
protein [with a LIM domain, (PFam E value 0.066), but not a pre-
dicted transmembrane helix as assessed using the TMHMM server
v. 2.0 accessed at http://www.cbs.dtu.dk/services/TMHMM/].
This gene cassette is conserved between ϕC2 and φCD27, with
each CDS having 100% identity at the aa level between the two
phages. The phage MMP02 also encodes a homolog of the third
CDS, which shares 100% identity with the genes of ϕC2 and
φCD27, but does not have either of the other two CDSs. Also
in CD119 we detected an unannotated CDS on the antisense
strand which contains a possible LIM protein domain (PFam
E-value 0.062), but not the other genes in the cassette, which high-
lights the high degree of mosaicism between these related phage
genomes.
The proposed lysogenic module of phiCDHM1 is notably
different to the other sequenced phages. It carries a cassette con-
taining gene homologs of the agr quorum sensing system. These
genes are not shared with any of the other C. difﬁcile phages. They
represent a third type of agr locus present in relatively few C.
difﬁcile strains (Hargreaves et al., 2013c).
Another marked feature is the RepR of CD119. Lysogenic
infection with CD119 has been found to reduce production of
TcdA and TcdB, and RepR appears to repress transcription of tcdA
and tcdR via binding of their promotor regions (Govind et al.,
2009). A blastp search of this gene against all the annotated ORFs
in each phage genome revealed homologs in phiCDHM1,ϕC2 and
CD6356; phiCDHM1_gp43 shares 30% identity with an E value
of 2e-11, the gene phiC2p50 has 35% identity with an E value of
6e-18 and, lastly, CD6356_38 has 27% identity and an E value
of 2-10. Whether these genes have homologous functions also
remains tobe investigatedbutwe canpredict that these phages have
genes with the capacity to inﬂuence cell physiology via regulatory
proteins.
A key ﬁnding from the study that sequenced the genome of
ϕC2 was that the PaLoc may have had a phage origin due to the
sequence similarity between the holin gene and tcdE (Goh et al.,
2007). This suggestion is further supported in the same study
by the identiﬁcation of a homolog of cdu1, Orf 46, which also
contains a Penicillinase R protein domain. The CDS is located
downstream of the lysogenic conversion module, on the sense
strand, and may have a regulatory function. Homologs are present
in CD119, phiCDHM1 and MMP02: phiCD119_gp42 has
48% identity and an E value of 1e-20, phiCDHM1 has two
homologs; CDHM1_gp40 has 47% identity and an E value of
1e-31 and CDHM1_gp39 has 31% identity and an E value of
5e-19; MMP02 also has two homologs; D863_gp39 has 31%
identity and an E value of 2-19 and D863_gp40 has 44% iden-
tity and an E value of 5e-27. The functions of these genes are not
known nor whether they would be the same for the compared
genes.
Lastly, another CDS with a predicted accessory function has
been identiﬁed in ϕC2, Orf37, which is a homolog of AbiF (Goh
et al., 2007). AbiF is a protein involved in phage abortive infection
[see review by Labrie et al. (2010)]. Homologs of this gene are not
present in any of the other C. difﬁcile phages and while Abi genes
are typically encoded by their bacterial hosts, they have been found
on a prophage element in Lactococcus lactis (Ventura et al., 2007)
and in the genome of L. lactis phage TP712 (Roces et al., 2013).
Although the mechanism by which AbiF performs its function
is not fully known (Garvey et al., 1995), the unusual presence of
this gene in the genome of phage ϕC2 suggests it could inhibit
secondary phage infection or modulate ϕC2 replication and may
contribute to the low frequencies reported for isolating free phages.
TAXONOMIC DIVERSITY OF THE C. difﬁcile PHAGES
The relatedness of the sequenced phage genomes can be seen in
Figure 3 which includes their sequence similarity at the nucleotide
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FIGURE 3 | Sequenced C. difﬁcile phage genome similarity and
content. Phage genomes were searched using tblastpx against one
another and genome maps were generated using EasyFigv2.1 (Sullivan
et al., 2011). The most similar phages are adjacent to one another,
phage names are on the left hand side and phage morphological type,
genome size and GC content are on the right hand side. The
acronyms designate long tailed myovirus (LTM), medium myovirus
(MM), small myovirus (SMV), and siphovirus (SV). Accession numbers
for each phage genome are as follows: MMP02 NC_019421.1; φCD27
NC_011398.1; ϕC2 NC_009231.1; phiCDHM1 HG531805; CD119
NC_007917.1; MMP04 NC_019422.1; ϕCD38-2 NC_015568.1;
CD6356 NC_015262.1. Speciﬁc genes are highlighted to shown their
conservation and position between genomes, and are discussed in the
text.
level, resulting from a tblastx analysis performed in EasyFig v.2.0
(Sullivan et al., 2011). The genome sizes vary from∼31 to∼56 kbp,
but all share a similarGCcontentwhich ranges between∼28–30%.
In addition to differences in length, the genomes of the SMVs and
the SVs are distinct in terms of their architecture compared to
the medium and LTMs. The structural genes are followed by a
lysis module, but in the genomes of the SMV and the SVs, the
predicted integrases are located following DNA metabolism and
DNA replication genes, on the sense strand. However, these phages
do have putative lysogenic conversion modules, which are located
immediately downstream of the lysis module in each genome.
This region encodes predicted proteins with putative accessory
functions including membrane or secreted proteins, and all three
encode a homolog of ParA, a protein involved in partitioning
DNA during cellular division (Bignell and Thomas, 2001). In the
genome of MMP04, there is a CDS, D864_gp28, which contains
a ﬂagella assembly protein domain, FliH (PFam E value 0.048), as
well as a CDS,D864_gp30, which contains a MazE domain (PFam
E value 0.025). This region in the two SVs is genetically similar,
despite the fact that these phages are of different replication types,
cos and pac, and that the regions containing structural genes are
highly divergent to one another.
The subject of taxonomy within C. difﬁcile myoviruses was
addressed by Lavigne et al. (2009) in a review which predates the
www.frontiersin.org April 2014 | Volume 5 | Article 184 | 9
Hargreaves and Clokie C. difﬁcile phages
publication of either C. difﬁcile SV or the SMV genomes. In this
review, the authors identiﬁed a DNA methylase gene and a DNA
replication cassette which are characteristic for the type species
CD119. This cassette contains three genes that encode DnaD,
a hypothetical protein and a single strand DNA binding protein.
The DNA methylase gene and cassette are labeled in Figure 3.
Although both of the SVs have a gene encoding a predicted single
strand DNA binding protein, the other genes are not present in
either the SV or SMV genomes and furthermore, these phages
do not share 40% of their genes to the type species CD119,
or to one another, so could each represent a novel phage type
species.
Notably these phage genomes contain divergent regions where
genes predicted to encode tail proteins and tail ﬁbers are located,
suggesting that these phages could target divergent receptors.
There is some similarity between the medium and SMVs in this
region of their genomes, and in conserved genes located within
it, but there is little to no similarity between the SVs at the aa
sequence level. In order to determine whether sequence informa-
tion can be used to guide phage selection for use in therapeutic
cocktails, investigation into the tertiary structures of the puta-
tive tail ﬁber sequences as well as co-absorption assays may be
helpful.
ALTERNATIVES TO THE USE OF “WHOLE PHAGE” TO TREAT
CDI
Themajor disadvantages that have been described against the ther-
apeutic use of C. difﬁcile phages are their narrow host ranges and
their ability to lysogenize strains of C. difﬁcile. To combat these
problems, one alternative approach for applying C. difﬁcile phage
biology in a therapeutic manner has been to clone and express a
recombinant version of the endolysin from φCD27 (Mayer et al.,
2008). Endolysins typically have a cell wall binding domain and
an amidase domain, which degrades the bacterial peptidoglycan
layer resulting in cell death and lysis. The endolysin has a wider
host range than the phage it has been cloned from, which suggests
the target of this enzyme in the peptidoglycan structure of differ-
entC. difﬁcile strains is less variable than that of the phage receptor
molecule (Mayer et al., 2008, 2011).
Although this is a non-replicating approach, the endolysin has
been cloned into L. lactis to demonstrate a proof of principle for
delivery to the gut and sites of infection (Mayer et al., 2008). The
further investigation of this endolysin found that a truncated ver-
sion of the N terminus was able to lyse all 32 strains of C. difﬁcile
tested, and lysed cells more rapidly and effectively than the intact
enzyme (Mayer et al., 2011). Surviving cells grew more slowly, and
presumably growth rate was subject to the cost of resistance or
cell damage. However, the effective host range was also broader,
as researchers found that strains of two other clostridial species
were lysed by both the intact and partial endolysin,C. sordellii and
C. bifermentans. The endolysin could also lyse less-closely related
species, B. amyloliquefaciens, B. cereus, and B. subtilis, Listeria
innocua, L. monocytogenes serovar 4, L. ivanovii NCTC 11007; and
as the researchers state, this may be explained by the fact that all
have a peptidoglycan type of A1γ. How this wider activity of the
truncated endolysin impacts upon on the microbial community
of the GI tract remains to be tested.
FUTURE DIRECTIONS
As discussed in this review, there are several potential beneﬁts
of using phage therapy to treat patients with CDI. Studies have
shown both the efﬁcacy of phages to clear and/or prevent infec-
tion and demonstrated the speciﬁcity of phages for targeting C.
difﬁcile in the gut microbial community. However, research into
the biology of these phages has also demonstrated a high fre-
quency of lysogeny by known phages and it has highlighted the
fact that phages may inﬂuence C. difﬁcile physiology when present
as prophages, or when infecting in the lytic cycle. These different
aspects of C. difﬁcile phage biology need to be addressed during
the development of any therapeutic using such phages. Lysogeny
is also undesirable due to the potential transfer of novel genetic
material into the recipient cell, and may make the bacterial cell
resistant to the phage therapy. This would mean that if the lyso-
gen was spread through a population, the cells that encoded it
could not be killed by the same phage that was being given as a
therapeutic.
These considerationsmotivate the continued attempts to isolate
strictly virulent phages, but there are also alternative strategies
which make use of existing phages. The emerging technology of
synthetic biology to alter phage host ranges or to synthesize a
strictly lytic phage by mutating a temperate phage is theoretically
possible. Such procedures have been achieved for other systems
and purposes, e.g., for enhancing antibiotic susceptibility of the
host bacterium (Lu and Collins, 2009). Furthermore, synthesizing
modiﬁed phages has been investigated for a number of pathogenic
bacteria such as E. coli and S. aureus [see review by Moradpour
and Ghasemian (2011)]. Genetic manipulation of the phage hosts
could also be performed to improve phage isolation or production,
as has beendone in other bacterial species, for example the removal
of prophage elements in Corynebacterium glutamicum (Baumgart
et al., 2013).
It is worth noting however, that the use of genetically modi-
ﬁed phages and indicator hosts could present further difﬁculties
to regulate their use. To avoid the use of GMOs, optimization of
existing techniques could be performed, such as continued passage
on speciﬁc strains to improve host ranges, as has been demon-
strated for P. aeruginosa (Betts et al., 2013), as well as to devise new
approaches, such as using lysogens generated from known phages
to screen for less related phages. Additionally, the characterization
of host ranges to include more determinant features as suggested
by Hyman and Abedon (2010) would aid in understanding the
biological parameters in this system.
Also, as yet, no experimental models have included the inves-
tigation of multiple phages or strains, and the application of
phage cocktails both in in vitro and in vivo models would help
determine their efﬁcacy against a range of C. difﬁcile strains.
Such experiments could show how resistance could be coun-
tered, as well as establish the signiﬁcance of lysogeny within a
multi-phage approach. Such work is currently underway in this
laboratory (UoL, 2013). Another option is to expand the mod-
els available to assess phage therapy, for example the use of ex
vivo models such as human epithelial cell lines is being researched
in our laboratory (unpublished data, this laboratory) as well as
mathematical modeling to assess host range data (unpublished
data, this laboratory).
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Concurrently, research into how to deliver phages and their
production is also required. Phage particles have been found to be
inherently stable under speciﬁc conditions (e.g., Hargreaves et al.,
2013a) and studies of C. difﬁcile phages have found they can be sta-
ble across a range of pHs and temperatures (Sell et al., 1983; Mayer
et al., 2008; Horgan et al., 2010), but stability is variable according
to different phages (Mahony et al., 1985), and the use of a bicar-
bonate buffer administered in an in vivo model was necessary
for phage viability (Ramesh et al., 1999). Problems with obtain-
ing high titres of phage has also been addressed and researchers
have optimized phage production by including divalent cations
to infected cultures, altering agar concentrations and by infecting
cultures at varying bacterial growth stages which have resulted in
phage titres as high as 1010 PFU/ml (Mahony et al., 1985; Goh
et al., 2005b; Horgan et al., 2010).
Aside from developing the production of a phage therapeu-
tic, further work is needed to establish the consequences of
phage infection on both the host bacterium and on the neigh-
boring microbial community. For example RNAseq data could
be used to generate transcriptomes, as has been done in other
systems, such as in a Pseudomonas phage infection model by
(Lavigne et al., 2013). In the same study, the authors also uti-
lized proteomic data to probe infection dynamics, highlighting
the usefulness of combining several methods of analysis to gain
an accurate insight into the temporal dynamics of phage infec-
tion. There are few published studies examining the C. difﬁcile
proteome (e.g., Chen et al., 2013), but they offer valuable data
and one such study revealed the presence of phage proteins in
CD630 spores (Lawley et al., 2009). Homologs of these genes are
highlighted in Figure 3, but how phage infection impacts upon
sporulation processes is not understood in this species, although it
has been well described in another endospore former, B. anthracis
(Schuch and Fischetti, 2009).
Next generation sequencing has also been applied to aid under-
standingof themechanisms facilitatingHGT in thenormal human
microbiota (e.g., Smillie et al., 2011). In C. difﬁcile, the PaLoc can
be transferred via conjugation as shown during in vitro experi-
ments (Brouwer et al., 2013). Understanding the levels of HGT
occurring during CDI would be useful in order to determine
how this could be impacted upon during phage treatment. It
is known that antibiotic treatment can modify the interactions
between phage and bacteria (Modi et al., 2013), but this has not
been examined for C. difﬁcile treatment models including anti-
body and antibiotic treatment (e.g., Peterfreund et al., 2012) and
bacteriocin treatment (Rea et al., 2011). As previously discussed,
more information on the bacterial and phage dynamics during
CDI would be helpful to assess the impact on prescribing phages
as therapeutics.
Research on C. difﬁcile phages has revealed key insights into
the evolution of this pathogenic bacterium as well as provid-
ing resources that can be exploited in many ways. This includes
the use of transducing phages, of phages as diagnostic agents, as
sources of therapeutic proteins, and indeed as therapeutic agents
themselves. To conclude, we concur that C. difﬁcile phages are
indeed still difﬁcult. They are technically demanding to isolate
and propagate and several aspects of their relationship with their
bacterial hosts are still unclear. However, their potential value
as therapeutics and the emergence of the new sequencing and
molecular tools available to researchers should provide answers
to the questions which underpin the successful development of a
phage-based therapeutic.
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